clinical trial · NCT06730542
Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
Juan P. Alderuccio, MD·phase1·recruiting·n = 20
CNS LymphomaZanubrutinibMethotrexatePolatuzumab VedotinRituximabCyclophosphamideDoxorubicinPrednisone
brief summary
The purpose of this study is to is to determine the effects (good and bad) of Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in patients with Secondary Central Nervous System (CNS) Lymphoma.
started
Apr 17, 2025
primary completion
Apr 30, 2030
completion
Apr 30, 2030
last updated
May 8, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol